Fonseca, Vivian A.

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M. (2009) · Diabetologia

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 141

COVID-19 in people living with diabetes: An international consensus

Caballero, A. E., Ceriello, A., Misra, A., Aschner, P., McDonnell, M. E., Hassanein, M., Ji, L., Mbanya, J. C., & Fonseca, V. A. (2020) · Journal of Diabetes and its Complications

COVID-19 Clinical Research StudiesDiabetes Management and Research

Cited by 132

Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence

Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 130

Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes

Umpierrez, G. E., Reyes, D., Smiley, D., Hermayer, K., Khan, A., Olson, D. E., Pasquel, F., Jacobs, S., Newton, C., Peng, L., et al. (2014) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 130

Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus

Woods, T. C., Satou, R., Miyata, K., Katsurada, A., Dugas, C. M., Klingenberg, N. C., Fonseca, V. A., & Navar, L. G. (2019) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 124

Acute painful diabetic neuropathy precipitated by strict glycaemic control

Llewelyn, J. G., Thomas, P. K., Fonseca, V., King, R. H. M., & Dandona, P. (1986) · Acta Neuropathologica

Pain Mechanisms and TreatmentsPeripheral Neuropathies and Disorders

Cited by 121

A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses

Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 115

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner

Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 104

Racial Disparity of Eye Examinations Among the U.S. Working-Age Population With Diabetes: 2002–2009

Shi, Q., Zhao, Y., Fonseca, V., Krousel-Wood, M., & Shi, L. (2014) · Diabetes Care

Retinal Diseases and TreatmentsHealth disparities and outcomes

Cited by 94

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis

Yoshida, Y., Joshi, P., Barri, S., Wang, J., Corder, A. L., O'Connell, S. S., & Fonseca, V. A. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementRetinal Diseases and Treatments

Cited by 65

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD trial

Tang, Y., Shah, H., Bueno Junior, C. R., Sun, X., Mitri, J., Sambataro, M., Sambado, L., Gerstein, H. C., Fonseca, V., Doria, A., et al. (2021) · Diabetes Care

Heart Rate Variability and Autonomic ControlDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 60

Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion

Thethi, T. K., Rao, A., Kawji, H., Mallik, T., Yau, C. L., Christians, U., & Fonseca, V. (2010) · Journal of Diabetes and its Complications

Diabetes Management and ResearchIntravenous Infusion Technology and Safety

Cited by 53

Safety of liraglutide in type 2 diabetes and chronic kidney disease

Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 50

Acute adrenal crisis precipitated by thyroxine.

Fonseca, V, Brown, R., Hochhauser, D., Ginsburg, J., & Havard, C. W. (1986) · BMJ

Adrenal Hormones and DisordersThyroid Disorders and Treatments

Cited by 44

Metabolic and Antihypertensive Effects of Combined Angiotensin Receptor Blocker and Diuretic Therapy in Prediabetic Hypertensive Patients With the Cardiometabolic Syndrome

Zappe, D. H., Sowers, J. R., Hsueh, W. A., Haffner, S. M., Deedwania, P. C., Fonseca, V. A., Keeling, L., & Sica, D. A. (2008) · The Journal of Clinical Hypertension

Blood Pressure and Hypertension StudiesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 42

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes: A Target Trial Emulation Study

Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine

Diabetes Treatment and ManagementSuicide and Self-Harm Studies

Cited by 40

A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes.

Yoshida, Y., Cheng, X., Shao, H., Fonseca, V. A., & Shi, L. (2020) · Current Diabetes Reports

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 39

Cardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents

Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 38

Economic burden of hypoglycemia in patients with type 2 diabetes

Liu, S., Zhao, Y., Hempe, J. M., Fonseca, V., & Shi, L. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 37

Socioeconomic factors play a more important role than clinical needs in the use of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes.

Shao, H., Li, P., Guo, J., Fonseca, V., Shi, L., & Zhang, P. (2022) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13

Predictors of Duloxetine versus Other Treatments among Veterans with Diabetic Peripheral Neuropathic Pain: A Retrospective Study

Zhao, Y., Liu, J., Zhao, Y., Thethi, T., Fonseca, V., & Shi, L. (2012) · Pain Practice

Pain Mechanisms and TreatmentsPain Management and Treatment

Cited by 10